# Agios Pharmaceuticals, Inc.: financial statements, quarterly

AGIO · Nasdaq · CIK 1439222 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/agio.md) · [Financials](/companies/agio/financials.md) · [Filings](/companies/agio/filings.md) · [Insiders](/companies/agio/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/agio/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [7.4](/filings/0001439222-24-000138.md) | [7.1 d](/filings/0001439222-26-000025.md) | [8.2](/filings/0001439222-25-000036.md) | [8.6](/filings/0001439222-25-000089.md) | [9.0](/filings/0001439222-25-000116.md) | [10.7 d](/filings/0001439222-26-000025.md) | [8.7](/filings/0001439222-26-000073.md) | [12.5](/filings/0001439222-26-000118.md) | [12.9](/filings/0001439222-25-000116.md) | [20.0 d](/filings/0001439222-26-000025.md) | [20.7](/filings/0001439222-26-000073.md) | [44.7](/filings/0001439222-26-000118.md) |
| Cost of revenue | $m | [0.6](/filings/0001439222-24-000138.md) | [0.6 d](/filings/0001439222-26-000025.md) | [0.6](/filings/0001439222-25-000036.md) | [1.5](/filings/0001439222-25-000089.md) | [0.8](/filings/0001439222-25-000116.md) | [1.3 d](/filings/0001439222-26-000025.md) | [1.1](/filings/0001439222-26-000073.md) | [1.7](/filings/0001439222-26-000118.md) | [1.7](/filings/0001439222-25-000116.md) | [1.9 d](/filings/0001439222-26-000025.md) | [1.3](/filings/0001439222-26-000073.md) | [3.0](/filings/0001439222-26-000118.md) |
| Research and development | $m | [81.8](/filings/0001439222-24-000138.md) | [77.5 d](/filings/0001439222-26-000025.md) | [68.6](/filings/0001439222-25-000036.md) | [77.4](/filings/0001439222-25-000089.md) | [72.5](/filings/0001439222-25-000116.md) | [82.8 d](/filings/0001439222-26-000025.md) | [72.7](/filings/0001439222-26-000073.md) | [91.9](/filings/0001439222-26-000118.md) | [86.8](/filings/0001439222-25-000116.md) | [88.1 d](/filings/0001439222-26-000025.md) | [81.1](/filings/0001439222-26-000073.md) | [101](/filings/0001439222-26-000118.md) |
| Selling, general and administrative | $m | [25.8](/filings/0001439222-24-000138.md) | [35.3 d](/filings/0001439222-26-000025.md) | [31.0](/filings/0001439222-25-000036.md) | [35.5](/filings/0001439222-25-000089.md) | [38.5](/filings/0001439222-25-000116.md) | [51.7 d](/filings/0001439222-26-000025.md) | [41.5](/filings/0001439222-26-000073.md) | [45.9](/filings/0001439222-26-000118.md) | [41.3](/filings/0001439222-25-000116.md) | [51.6 d](/filings/0001439222-26-000025.md) | [48.3](/filings/0001439222-26-000073.md) | [51.5](/filings/0001439222-26-000118.md) |
| Operating income | $m | [(101)](/filings/0001439222-24-000138.md) | [(106) d](/filings/0001439222-26-000025.md) | [(92.1)](/filings/0001439222-25-000036.md) | [(106)](/filings/0001439222-25-000089.md) | [(103)](/filings/0001439222-25-000116.md) | [(125) d](/filings/0001439222-26-000025.md) | [(107)](/filings/0001439222-26-000073.md) | [(127)](/filings/0001439222-26-000118.md) | [(117)](/filings/0001439222-25-000116.md) | [(122) d](/filings/0001439222-26-000025.md) | [(110)](/filings/0001439222-26-000073.md) | [(111)](/filings/0001439222-26-000118.md) |
| Income tax | $m | [0.0](/filings/0001439222-24-000138.md) | [0.0 d](/filings/0001439222-26-000025.md) | not reported | not reported | [53.1](/filings/0001439222-25-000116.md) | [(8.9) d](/filings/0001439222-26-000025.md) | not reported | not reported | [0.0](/filings/0001439222-25-000116.md) | [(1.0) d](/filings/0001439222-26-000025.md) | not reported | not reported |
| Net income | $m | [(91.3)](/filings/0001439222-24-000138.md) | [(95.9) d](/filings/0001439222-26-000025.md) | [(81.5)](/filings/0001439222-25-000116.md) | [(96.1)](/filings/0001439222-25-000116.md) | [948](/filings/0001439222-25-000116.md) | [(96.5) d](/filings/0001439222-26-000025.md) | [(89.3)](/filings/0001439222-26-000118.md) | [(112)](/filings/0001439222-26-000118.md) | [(103)](/filings/0001439222-25-000116.md) | [(108) d](/filings/0001439222-26-000025.md) | [(99.1)](/filings/0001439222-26-000118.md) | [(101)](/filings/0001439222-26-000118.md) |
| Diluted EPS | $ per share | [(1.64)](/filings/0001439222-24-000138.md) | not reported | [(1.45)](/filings/0001439222-25-000036.md) | [(1.69)](/filings/0001439222-25-000089.md) | [16.22](/filings/0001439222-25-000116.md) | not reported | [(1.55)](/filings/0001439222-26-000073.md) | [(1.93)](/filings/0001439222-26-000118.md) | [(1.78)](/filings/0001439222-25-000116.md) | not reported | [(1.69)](/filings/0001439222-26-000073.md) | [(1.69)](/filings/0001439222-26-000118.md) |
| Basic EPS | $ per share | [(1.64)](/filings/0001439222-24-000138.md) | not reported | [(1.45)](/filings/0001439222-25-000036.md) | [(1.69)](/filings/0001439222-25-000089.md) | [16.65](/filings/0001439222-25-000116.md) | not reported | [(1.55)](/filings/0001439222-26-000073.md) | [(1.93)](/filings/0001439222-26-000118.md) | [(1.78)](/filings/0001439222-25-000116.md) | not reported | [(1.69)](/filings/0001439222-26-000073.md) | [(1.69)](/filings/0001439222-26-000118.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [64.3](/filings/0001439222-23-000140.md) | [88.2](/filings/0001439222-25-000009.md) | [119](/filings/0001439222-24-000069.md) | [84.5](/filings/0001439222-24-000121.md) | [254](/filings/0001439222-24-000138.md) | [76.2](/filings/0001439222-26-000025.md) | [79.0](/filings/0001439222-25-000036.md) | [80.9](/filings/0001439222-25-000089.md) | [92.7](/filings/0001439222-25-000116.md) | [89.1](/filings/0001439222-26-000118.md) | [114](/filings/0001439222-26-000073.md) | [99.6](/filings/0001439222-26-000118.md) |
| Current assets | $m | [704](/filings/0001439222-23-000140.md) | [834](/filings/0001439222-25-000009.md) | [664](/filings/0001439222-24-000069.md) | [632](/filings/0001439222-24-000121.md) | [1,074](/filings/0001439222-24-000138.md) | [966](/filings/0001439222-26-000025.md) | [969](/filings/0001439222-25-000036.md) | [1,019](/filings/0001439222-25-000089.md) | [1,033](/filings/0001439222-25-000116.md) | [942](/filings/0001439222-26-000118.md) | [835](/filings/0001439222-26-000073.md) | [718](/filings/0001439222-26-000118.md) |
| Total assets | $m | [1,007](/filings/0001439222-23-000140.md) | [937](/filings/0001439222-25-000009.md) | [850](/filings/0001439222-24-000069.md) | [773](/filings/0001439222-24-000121.md) | [1,792](/filings/0001439222-24-000138.md) | [1,663](/filings/0001439222-26-000025.md) | [1,556](/filings/0001439222-25-000036.md) | [1,471](/filings/0001439222-25-000089.md) | [1,386](/filings/0001439222-25-000116.md) | [1,297](/filings/0001439222-26-000118.md) | [1,185](/filings/0001439222-26-000073.md) | [1,108](/filings/0001439222-26-000118.md) |
| Current liabilities | $m | [58.4](/filings/0001439222-23-000140.md) | [68.0](/filings/0001439222-25-000009.md) | [51.7](/filings/0001439222-24-000069.md) | [62.6](/filings/0001439222-24-000121.md) | [119](/filings/0001439222-24-000138.md) | [81.2](/filings/0001439222-26-000025.md) | [52.4](/filings/0001439222-25-000036.md) | [70.4](/filings/0001439222-25-000089.md) | [74.8](/filings/0001439222-25-000116.md) | [82.2](/filings/0001439222-26-000118.md) | [58.8](/filings/0001439222-26-000073.md) | [70.2](/filings/0001439222-26-000118.md) |
| Total liabilities | $m | [120](/filings/0001439222-23-000140.md) | [126](/filings/0001439222-25-000009.md) | [106](/filings/0001439222-24-000069.md) | [113](/filings/0001439222-24-000121.md) | [165](/filings/0001439222-24-000138.md) | [122](/filings/0001439222-26-000025.md) | [89.0](/filings/0001439222-25-000036.md) | [102](/filings/0001439222-25-000089.md) | [101](/filings/0001439222-25-000116.md) | [104](/filings/0001439222-26-000118.md) | [75.9](/filings/0001439222-26-000073.md) | [82.4](/filings/0001439222-26-000118.md) |
| Shareholders' equity | $m | [887](/filings/0001439222-24-000138.md) | [811](/filings/0001439222-26-000025.md) | [744](/filings/0001439222-25-000116.md) | [661](/filings/0001439222-25-000116.md) | [1,627](/filings/0001439222-25-000116.md) | [1,541](/filings/0001439222-26-000118.md) | [1,467](/filings/0001439222-26-000118.md) | [1,370](/filings/0001439222-26-000118.md) | [1,284](/filings/0001439222-25-000116.md) | [1,193](/filings/0001439222-26-000118.md) | [1,109](/filings/0001439222-26-000118.md) | [1,026](/filings/0001439222-26-000118.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(61.6) d](/filings/0001439222-24-000138.md) | [(72.5) d](/filings/0001439222-26-000025.md) | [(99.9)](/filings/0001439222-25-000036.md) | [(72.6) d](/filings/0001439222-25-000089.md) | [(84.2) d](/filings/0001439222-25-000116.md) | [(133) d](/filings/0001439222-26-000025.md) | [(111)](/filings/0001439222-26-000073.md) | [(77.1) d](/filings/0001439222-26-000118.md) | [(88.2) d](/filings/0001439222-25-000116.md) | [(96.2) d](/filings/0001439222-26-000025.md) | [(119)](/filings/0001439222-26-000073.md) | [(57.3) d](/filings/0001439222-26-000118.md) |
| Capital expenditure | $m | [0.4 d](/filings/0001439222-24-000138.md) | [0.2 d](/filings/0001439222-26-000025.md) | [0.1](/filings/0001439222-25-000036.md) | [0.2 d](/filings/0001439222-25-000089.md) | [0.4 d](/filings/0001439222-25-000116.md) | [1.0 d](/filings/0001439222-26-000025.md) | [0.8](/filings/0001439222-26-000073.md) | [0.9 d](/filings/0001439222-26-000118.md) | [1.6 d](/filings/0001439222-25-000116.md) | [1.1 d](/filings/0001439222-26-000025.md) | [0.8](/filings/0001439222-26-000073.md) | [1.2 d](/filings/0001439222-26-000118.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [54.8](/filings/0001439222-23-000140.md) | [55.3](/filings/0001439222-24-000069.md) | [55.6](/filings/0001439222-24-000121.md) | [55.8](/filings/0001439222-24-000138.md) | [56.4](/filings/0001439222-25-000036.md) | [56.8](/filings/0001439222-25-000089.md) | [58.4](/filings/0001439222-25-000116.md) | [57.5](/filings/0001439222-26-000073.md) | [57.9](/filings/0001439222-26-000118.md) | [58.1](/filings/0001439222-25-000116.md) | [58.8](/filings/0001439222-26-000073.md) | [59.5](/filings/0001439222-26-000118.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 59,701,882 at 2026-07-24, from the cover of the [10-Q filed 2026-07-30](/filings/0001439222-26-000118.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.